Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients

Abstract Background Although the efficacy of iron sucrose (IS) and ferric carboxymaltose (FCM) in treating anemia in hemodialysis (HD) patients has been studied individually, a comparison of these two intravenous iron formulations has not yet been performed in HD patients. Methods We performed a ret...

Full description

Bibliographic Details
Main Authors: Jesse M. G. Hofman, Michele F. Eisenga, Adry Diepenbroek, Ilja M. Nolte, Bastiaan van Dam, Ralf Westerhuis, Stephan J. L. Bakker, Casper F. M. Franssen, Carlo A. J. M. Gaillard
Format: Article
Language:English
Published: BMC 2018-09-01
Series:BMC Nephrology
Subjects:
ESA
Online Access:http://link.springer.com/article/10.1186/s12882-018-1045-8
id doaj-fff6c37198b74854a2722e7fbb25c7e2
record_format Article
spelling doaj-fff6c37198b74854a2722e7fbb25c7e22020-11-24T21:27:41ZengBMCBMC Nephrology1471-23692018-09-011911810.1186/s12882-018-1045-8Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patientsJesse M. G. Hofman0Michele F. Eisenga1Adry Diepenbroek2Ilja M. Nolte3Bastiaan van Dam4Ralf Westerhuis5Stephan J. L. Bakker6Casper F. M. Franssen7Carlo A. J. M. Gaillard8Department of Nephrology, University Medical Center Groningen, University of GroningenDepartment of Nephrology, University Medical Center Groningen, University of GroningenDepartment of Nephrology, University Medical Center Groningen, University of GroningenDepartment of Epidemiology, University Medical Center Groningen, University of GroningenDepartment of Internal Medicine, Medical Center AlkmaarDialysis Center GroningenDepartment of Nephrology, University Medical Center Groningen, University of GroningenDepartment of Nephrology, University Medical Center Groningen, University of GroningenDepartment of Internal Medicine and Dermatology, University Medical Center Utrecht, University of UtrechtAbstract Background Although the efficacy of iron sucrose (IS) and ferric carboxymaltose (FCM) in treating anemia in hemodialysis (HD) patients has been studied individually, a comparison of these two intravenous iron formulations has not yet been performed in HD patients. Methods We performed a retrospective audit on records of 221 stable HD patients from different HD centers in the Netherlands, who were switched from IS to FCM on a 1:1 ratio. To assess the effect of the switch on iron status parameters, data from 3 time points before and 3 time points after the switch were analyzed using linear mixed effects models. Subanalyses were done in 2 subgroups of patients anemic or iron deficient at baseline. Results Hemoglobin increased in all groups (anemic [1.4 g/dL, P < 0.001] iron deficient [0.6 g/dL, P < 0.001]), while the weekly iron dose was significantly lower when patients received FCM compared to IS (48 vs 55 mg/week, P = 0.04). Furthermore, serum ferritin and transferrin saturation increased in all groups (anemic [64 μg/L, 5.0%, P < 0.001] iron deficient [76 μg/L, 3.6%, P < 0.001]). Finally, the darbepoetin α dose decreased significantly in all groups (anemic [− 16 μg/wk., P = 0.01] iron deficient [− 11 μg/wk., P < 0.001]). Conclusions In this real-life study in HD patients, a switch from IS to FCM resulted in an improvement of iron status parameters despite a lower weekly dose of FCM. Furthermore, the ESA dose was reduced during FCM, while hemoglobin levels increased.http://link.springer.com/article/10.1186/s12882-018-1045-8Ferric carboxymaltoseIron sucroseHemodialysisIron statusESA
collection DOAJ
language English
format Article
sources DOAJ
author Jesse M. G. Hofman
Michele F. Eisenga
Adry Diepenbroek
Ilja M. Nolte
Bastiaan van Dam
Ralf Westerhuis
Stephan J. L. Bakker
Casper F. M. Franssen
Carlo A. J. M. Gaillard
spellingShingle Jesse M. G. Hofman
Michele F. Eisenga
Adry Diepenbroek
Ilja M. Nolte
Bastiaan van Dam
Ralf Westerhuis
Stephan J. L. Bakker
Casper F. M. Franssen
Carlo A. J. M. Gaillard
Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients
BMC Nephrology
Ferric carboxymaltose
Iron sucrose
Hemodialysis
Iron status
ESA
author_facet Jesse M. G. Hofman
Michele F. Eisenga
Adry Diepenbroek
Ilja M. Nolte
Bastiaan van Dam
Ralf Westerhuis
Stephan J. L. Bakker
Casper F. M. Franssen
Carlo A. J. M. Gaillard
author_sort Jesse M. G. Hofman
title Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients
title_short Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients
title_full Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients
title_fullStr Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients
title_full_unstemmed Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients
title_sort switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients
publisher BMC
series BMC Nephrology
issn 1471-2369
publishDate 2018-09-01
description Abstract Background Although the efficacy of iron sucrose (IS) and ferric carboxymaltose (FCM) in treating anemia in hemodialysis (HD) patients has been studied individually, a comparison of these two intravenous iron formulations has not yet been performed in HD patients. Methods We performed a retrospective audit on records of 221 stable HD patients from different HD centers in the Netherlands, who were switched from IS to FCM on a 1:1 ratio. To assess the effect of the switch on iron status parameters, data from 3 time points before and 3 time points after the switch were analyzed using linear mixed effects models. Subanalyses were done in 2 subgroups of patients anemic or iron deficient at baseline. Results Hemoglobin increased in all groups (anemic [1.4 g/dL, P < 0.001] iron deficient [0.6 g/dL, P < 0.001]), while the weekly iron dose was significantly lower when patients received FCM compared to IS (48 vs 55 mg/week, P = 0.04). Furthermore, serum ferritin and transferrin saturation increased in all groups (anemic [64 μg/L, 5.0%, P < 0.001] iron deficient [76 μg/L, 3.6%, P < 0.001]). Finally, the darbepoetin α dose decreased significantly in all groups (anemic [− 16 μg/wk., P = 0.01] iron deficient [− 11 μg/wk., P < 0.001]). Conclusions In this real-life study in HD patients, a switch from IS to FCM resulted in an improvement of iron status parameters despite a lower weekly dose of FCM. Furthermore, the ESA dose was reduced during FCM, while hemoglobin levels increased.
topic Ferric carboxymaltose
Iron sucrose
Hemodialysis
Iron status
ESA
url http://link.springer.com/article/10.1186/s12882-018-1045-8
work_keys_str_mv AT jessemghofman switchingironsucrosetoferriccarboxymaltoseassociatestobettercontrolofironstatusinhemodialysispatients
AT michelefeisenga switchingironsucrosetoferriccarboxymaltoseassociatestobettercontrolofironstatusinhemodialysispatients
AT adrydiepenbroek switchingironsucrosetoferriccarboxymaltoseassociatestobettercontrolofironstatusinhemodialysispatients
AT iljamnolte switchingironsucrosetoferriccarboxymaltoseassociatestobettercontrolofironstatusinhemodialysispatients
AT bastiaanvandam switchingironsucrosetoferriccarboxymaltoseassociatestobettercontrolofironstatusinhemodialysispatients
AT ralfwesterhuis switchingironsucrosetoferriccarboxymaltoseassociatestobettercontrolofironstatusinhemodialysispatients
AT stephanjlbakker switchingironsucrosetoferriccarboxymaltoseassociatestobettercontrolofironstatusinhemodialysispatients
AT casperfmfranssen switchingironsucrosetoferriccarboxymaltoseassociatestobettercontrolofironstatusinhemodialysispatients
AT carloajmgaillard switchingironsucrosetoferriccarboxymaltoseassociatestobettercontrolofironstatusinhemodialysispatients
_version_ 1725973944870109184